At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
TAS 102 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
SHORT: SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer, a Phase II Trial
In Brief
A Phase 2 clinical trial evaluating TAS 102 and Oxaliplatin for Rectal Cancer. Completed, enrolled 13 participants across 4 sites.
Detailed Summary
TASOX can be safely and efficaciously delivered after short course radiation, resulting in significant pathologic downstaging, allowing for an R0 pelvic resection, and providing local control in appropriately selected stage II/III rectal cancer patients treated with contemporary TME-based surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRectal Cancer
CountriesUnited States
CollaboratorsTaiho Oncology
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJul 2022
Primary CompletionDec 2023
Study CompletionFeb 2024
TodayJul 2026
First PostedJun 5, 2020
Enrollment StartJul 5, 2022
Primary CompletionDec 14, 2023
Study CompletionFeb 21, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 6.1 years ago
Interventions
TAS 102drug
Oral medication over Days 1-5
Oxaliplatindrug
Administered by intravenous infusion over 2 hours on day 1